Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates
17 Pág.
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | artículo biblioteca |
| Language: | English |
| Published: |
Frontiers Media
2023-12-12
|
| Subjects: | COVID-19, MVA-based vaccine, S protein, SARS-CoV-2, Efficacy, Immunogenicity, Mice, Variants of concern, |
| Online Access: | http://hdl.handle.net/10261/349371 http://dx.doi.org/10.13039/501100003339 http://dx.doi.org/10.13039/501100004837 http://dx.doi.org/10.13039/501100004587 http://dx.doi.org/10.13039/501100000780 http://dx.doi.org/10.13039/501100011033 https://api.elsevier.com/content/abstract/scopus_id/85180695762 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| id |
dig-inia-es-10261-349371 |
|---|---|
| record_format |
koha |
| institution |
INIA ES |
| collection |
DSpace |
| country |
España |
| countrycode |
ES |
| component |
Bibliográfico |
| access |
En linea |
| databasecode |
dig-inia-es |
| tag |
biblioteca |
| region |
Europa del Sur |
| libraryname |
Biblioteca del INIA España |
| language |
English |
| topic |
COVID-19 MVA-based vaccine S protein SARS-CoV-2 Efficacy Immunogenicity Mice Variants of concern COVID-19 MVA-based vaccine S protein SARS-CoV-2 Efficacy Immunogenicity Mice Variants of concern |
| spellingShingle |
COVID-19 MVA-based vaccine S protein SARS-CoV-2 Efficacy Immunogenicity Mice Variants of concern COVID-19 MVA-based vaccine S protein SARS-CoV-2 Efficacy Immunogenicity Mice Variants of concern Pérez Ramírez, Patricia Albericio, Guillermo Astorgano, David Flores, Sara Sánchez-Corzo, Cristina Sánchez-Cordón, P. J. Luczkowiak, Joanna Delgado, Rafael Casasnovas, José María Esteban, Mariano García-Arriaza, Juan Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates |
| description |
17 Pág. |
| author2 |
Ministerio de Sanidad (España) |
| author_facet |
Ministerio de Sanidad (España) Pérez Ramírez, Patricia Albericio, Guillermo Astorgano, David Flores, Sara Sánchez-Corzo, Cristina Sánchez-Cordón, P. J. Luczkowiak, Joanna Delgado, Rafael Casasnovas, José María Esteban, Mariano García-Arriaza, Juan |
| format |
artículo |
| topic_facet |
COVID-19 MVA-based vaccine S protein SARS-CoV-2 Efficacy Immunogenicity Mice Variants of concern |
| author |
Pérez Ramírez, Patricia Albericio, Guillermo Astorgano, David Flores, Sara Sánchez-Corzo, Cristina Sánchez-Cordón, P. J. Luczkowiak, Joanna Delgado, Rafael Casasnovas, José María Esteban, Mariano García-Arriaza, Juan |
| author_sort |
Pérez Ramírez, Patricia |
| title |
Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates |
| title_short |
Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates |
| title_full |
Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates |
| title_fullStr |
Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates |
| title_full_unstemmed |
Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates |
| title_sort |
preclinical immune efficacy against sars-cov-2 beta b.1.351 variant by mva-based vaccine candidates |
| publisher |
Frontiers Media |
| publishDate |
2023-12-12 |
| url |
http://hdl.handle.net/10261/349371 http://dx.doi.org/10.13039/501100003339 http://dx.doi.org/10.13039/501100004837 http://dx.doi.org/10.13039/501100004587 http://dx.doi.org/10.13039/501100000780 http://dx.doi.org/10.13039/501100011033 https://api.elsevier.com/content/abstract/scopus_id/85180695762 |
| work_keys_str_mv |
AT perezramirezpatricia preclinicalimmuneefficacyagainstsarscov2betab1351variantbymvabasedvaccinecandidates AT albericioguillermo preclinicalimmuneefficacyagainstsarscov2betab1351variantbymvabasedvaccinecandidates AT astorganodavid preclinicalimmuneefficacyagainstsarscov2betab1351variantbymvabasedvaccinecandidates AT floressara preclinicalimmuneefficacyagainstsarscov2betab1351variantbymvabasedvaccinecandidates AT sanchezcorzocristina preclinicalimmuneefficacyagainstsarscov2betab1351variantbymvabasedvaccinecandidates AT sanchezcordonpj preclinicalimmuneefficacyagainstsarscov2betab1351variantbymvabasedvaccinecandidates AT luczkowiakjoanna preclinicalimmuneefficacyagainstsarscov2betab1351variantbymvabasedvaccinecandidates AT delgadorafael preclinicalimmuneefficacyagainstsarscov2betab1351variantbymvabasedvaccinecandidates AT casasnovasjosemaria preclinicalimmuneefficacyagainstsarscov2betab1351variantbymvabasedvaccinecandidates AT estebanmariano preclinicalimmuneefficacyagainstsarscov2betab1351variantbymvabasedvaccinecandidates AT garciaarriazajuan preclinicalimmuneefficacyagainstsarscov2betab1351variantbymvabasedvaccinecandidates |
| _version_ |
1802819898729037824 |
| spelling |
dig-inia-es-10261-3493712024-05-21T07:02:07Z Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates Pérez Ramírez, Patricia Albericio, Guillermo Astorgano, David Flores, Sara Sánchez-Corzo, Cristina Sánchez-Cordón, P. J. Luczkowiak, Joanna Delgado, Rafael Casasnovas, José María Esteban, Mariano García-Arriaza, Juan Ministerio de Sanidad (España) Instituto de Salud Carlos III Conferencia de Rectores de las Universidades Españolas Consejo Superior de Investigaciones Científicas (España) Fundación la Caixa Ministerio de Ciencia e Innovación (España) Agencia Estatal de Investigación (España) European Commission Albericio, Guillermo [0000-0003-0190-4848] Astorgano, David [0000-0002-2969-1840] Sánchez-Cordón, P. J. [0000-0002-7202-6475] Luczkowiak, Joanna [0000-0001-6950-9372] Delgado, Rafael [0000-0002-6912-4736] Esteban, Mariano [0000-0003-0846-2827] García-Arriaza, Juan [0000-0002-5167-5724] COVID-19 MVA-based vaccine S protein SARS-CoV-2 Efficacy Immunogenicity Mice Variants of concern 17 Pág. The constant appearance of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VoCs) has jeopardized the protective capacity of approved vaccines against coronavirus disease-19 (COVID-19). For this reason, the generation of new vaccine candidates adapted to the emerging VoCs is of special importance. Here, we developed an optimized COVID-19 vaccine candidate using the modified vaccinia virus Ankara (MVA) vector to express a full-length prefusion-stabilized SARS-CoV-2 spike (S) protein, containing 3 proline (3P) substitutions in the S protein derived from the beta (B.1.351) variant, termed MVA-S(3Pbeta). Preclinical evaluation of MVA-S(3Pbeta) in head-to-head comparison to the previously generated MVA-S(3P) vaccine candidate, expressing a full-length prefusion-stabilized Wuhan S protein (with also 3P substitutions), demonstrated that two intramuscular doses of both vaccine candidates fully protected transgenic K18-hACE2 mice from a lethal challenge with SARS-CoV-2 beta variant, reducing mRNA and infectious viral loads in the lungs and in bronchoalveolar lavages, decreasing lung histopathological lesions and levels of proinflammatory cytokines in the lungs. Vaccination also elicited high titers of anti-S Th1-biased IgGs and neutralizing antibodies against ancestral SARS-CoV-2 Wuhan strain and VoCs alpha, beta, gamma, delta, and omicron. In addition, similar systemic and local SARS-CoV-2 S-specific CD4+ and CD8+ T-cell immune responses were elicited by both vaccine candidates after a single intranasal immunization in C57BL/6 mice. These preclinical data support clinical evaluation of MVA-S(3Pbeta) and MVA-S(3P), to explore whether they can diversify and potentially increase recognition and protection of SARS-CoV-2 VoCs. The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was supported by Fondo COVID-19 grant COV20/00151 (Spanish Health Ministry, Instituto de Salud Carlos III (ISCIII)), Fondo Supera COVID-19 grant (Crue Universidades-Banco Santander), and Spanish Research Council (CSIC) grant 202120E079 (to JG-A); CSIC grant 2020E84, la Caixa Banking Foundation grant CF01-00008, Ferrovial, and MAPFRE donations (to ME); and Spanish Ministry of Science and Innovation (MCIN)/Spanish Research Agency (AEI)/10.13039/501100011033 grant (PID2020-114481RB-I00; to JG-A and ME). This research work was also funded by the European Commission-Next Generation EU, through CSIC’s Global Health Platform (PTI Salud Global) (to JG-A and ME). JG-A and ME acknowledges financial support from the Spanish State Research Agency, AEI/10.13039/501100011033, through the “Severo Ochoa” Programme for Centres of Excellence in R&D (SEV-2013-0347, SEV-2017-0712). JC acknowledges MCIN and CSIC support (project number 202020E079). RD received grants from ISCIII (FIS PI2100989), the European Commission Horizon 2020 Framework Programme (Project VIRUSCAN FETPROACT-2016: 731868 and Project EPIC-CROWN-2: 101046084), and Fundacioín Caixa-Health Research HR18-00469 (Project StopEbola). Peer reviewed 2024-03-06T07:18:37Z 2024-03-06T07:18:37Z 2023-12-12 artículo http://purl.org/coar/resource_type/c_6501 Frontiers in Immunology 14: e1264323 (2023) http://hdl.handle.net/10261/349371 10.3389/fimmu.2023.1264323 1664-3224 http://dx.doi.org/10.13039/501100003339 http://dx.doi.org/10.13039/501100004837 http://dx.doi.org/10.13039/501100004587 http://dx.doi.org/10.13039/501100000780 http://dx.doi.org/10.13039/501100011033 38155964 2-s2.0-85180695762 https://api.elsevier.com/content/abstract/scopus_id/85180695762 en #PLACEHOLDER_PARENT_METADATA_VALUE# #PLACEHOLDER_PARENT_METADATA_VALUE# info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2020-114481RB-I00/ES/DESARROLLO, FUNCION INMUNE Y EFICACIA DE CANDIDATOS VACUNALES FRENTE AL SARS-COV-2%2FCOVID-19 BASADOS EN EL VECTOR POXVIRUS MVA/ info:eu-repo/grantAgreement/EC/H2020/731868 Frontiers in immunology Publisher's version https://doi.org/10.3389/fimmu.2023.1264323 Sí open application/pdf Frontiers Media |